Sarcopenia and muscle aging

Sarcopenia, the progressive loss of muscle mass and function with age, predicts how long you live more reliably than most lab tests your doctor orders. Low grip strength outperforms many standard clinical biomarkers for all-cause mortality [1]. Yet muscle loss gets a fraction of the attention directed at cardiovascular disease, despite being more prevalent in the oldest-old and more directly reversible.

The mechanism: mTOR is the problem, not the solution

For decades, the dominant theory held that aging muscle suffers from blunted anabolic signaling, too little mTORC1 activity, too little protein synthesis, gradual wasting. The primary evidence has reversed this picture.

In aged muscle, mTORC1 is chronically hyperactivated. Tang et al. (2019, Aging Cell) showed that both TSC1-knockout mice with constitutive mTORC1 activation and naturally aged mice exhibit the same downstream cascade: sustained mTORC1 drives GDF15/STAT3 signaling, oxidative damage, and progressive fiber degeneration. Human aged muscle biopsies show the identical over-activation pattern. Rapamycin fully rescued fiber integrity in both models [2]. Separately, Castets et al. (2013, Cell Metabolism) demonstrated that sustained mTORC1 in TSC1-deficient muscle blocks autophagy by inhibiting Ulk1, causing late-onset myopathy that rapamycin again reversed [3]. The block is on autophagic flux, the cell's capacity to clear damaged organelles, not on protein synthesis directly.

This explains an apparent paradox: intermittent mTOR suppression can preserve aged muscle rather than depleting it, because the pathology is chronic over-activation, not under-activation.

A parallel mechanism is also real and does not contradict the above. Older muscle shows anabolic resistance: it requires a higher leucine stimulus to trigger the same muscle protein synthesis (MPS) response as young muscle [4]. Chronic mTOR over-activation and blunted acute anabolic response describe different aspects of the same dysfunctional system.

Resistance training is the foundation

No intervention comes close to resistance training for preserving muscle in older adults. A meta-analysis of 49 studies (n=1,328, adults 50+) found a pooled lean body mass gain of +1.1 kg (95% CI: 0.9-1.2 kg) versus non-exercising controls, with a confirmed dose-response, higher volume programs produced greater gains [5]. A Cochrane review of 121 RCTs (~6,700 participants aged 60-89+) found a large positive effect on muscle strength (SMD 0.84), improved gait speed (+0.08 m/s), and better chair-rise ability (SMD -0.94); serious adverse events were rare, and effects held in people with comorbidities [6].

Resistance training is also safe at high intensity in older populations with bone concerns. The LIFTMOR trial showed high-intensity resistance training three times per week over eight weeks significantly improved lumbar bone mineral density (~4%) in postmenopausal women with osteopenia [7].

Protein: how much and how distributed

A 49-study meta-analysis set the dose-response plateau for MPS at 1.6 g/kg/day of total daily protein in healthy adults [8]. Above that, returns flatten.

For older adults, per-meal distribution matters as much as daily total. The leucine threshold, the minimum dose needed to maximally trigger MPS, is higher in older muscle: approximately 0.4 g/kg per meal versus 0.24 g/kg in younger adults. Spreading protein across three or more meals, with substantial leucine at each, is supported by the evidence on anabolic resistance [4].

Creatine and omega-3: additive, not primary

Creatine supplementation during resistance training produces significantly greater lean mass gains than resistance training alone, in a benefit not attributable to water retention [9]. The ISSN position supports 3-5 g/day; loading at 20 g/day for 5-7 days may accelerate muscle saturation [10]. Much of the benefit is indirect: more available ATP during high-intensity effort allows greater training volume and progressive overload [11, 10].

Omega-3 fatty acids work differently, they reduce anabolic resistance rather than building muscle directly. In adults aged 60-85-3.36 g/day of EPA+DHA for six months produced +3.6% thigh muscle volume, +2.3 kg grip strength, and +4.0% improvement in one-rep max [12]. Krill oil at 4 g/day for six months in adults over 65 significantly improved knee extensor torque, grip strength, and vastus lateralis thickness [13]. The disuse-atrophy protection may be most clinically relevant: pre-loading 5 g/day of fish oil before two weeks of immobilization reduced muscle volume loss by roughly 43% (8% vs 14%) compared to placebo [14].

Two signals worth watching

GLP-1 agonists: In the STEP 1 semaglutide trial, approximately 37-39% of total weight lost was lean body mass [15]. The cardiovascular benefits are real (SELECT trial, [16]), but clinicians using these drugs in patients with already-low muscle mass face a genuine trade-off. Resistance training and adequate protein during GLP-1 therapy are the currently accepted mitigation strategy.

NMN and exercise timing: A small trial (n=11) found that NMN suppressed post-exercise cytokines but also abolished the normal mitochondrial adaptation signal after blood-flow restriction exercise [17]. If replicated, taking NMN close to a training session may blunt the adaptations that sarcopenia management depends on. The sample size demands caution before drawing clinical conclusions.

Where the evidence is contested

Best daily protein target for older adults. The primary meta-analysis (Morton 2018) places the MPS dose-response plateau at 1.6 g/kg/day [8]. Gabrielle Lyon recommends 2.2 g/kg/day for older adults pursuing body recomposition [18]. This gap matters most for frail elderly patients, in whom appetite and digestive tolerance limit intake. Neither position is unreasonable given the evidence base. But they are not the same recommendation. The higher target has not been tested in a powered RCT in the frail elderly population, the group in whom it matters most.

Senescent cells and resistance training. Does resistance training reduce the burden of senescent cells (p16+, p21+) in older adult muscle? The question remains open. Von Ruff et al. (2025) found that 12 weeks of resistance training in men aged ~72 significantly reduced SASP-related gene expression in vastus lateralis biopsies. The canonical senescence markers CDKN1A (p21), CDKN2A (p16), and TP53 did not change significantly [19]. A systematic review of RCTs (n=1,447 across three trials, ages 66-79) confirmed that no trial has yet measured p16 or p21 directly. Meta-analysis of SASP cytokines found no significant exercise effect in older adults [20]. Adjacent evidence from a disuse/re-ambulation study suggests older adult muscle can reduce senescent markers in response to activity [21]. That context, recovery from bed rest, differs from structured resistance training in healthy older adults. The gap remains open.

References

1. Leong et al. 2015, Lancet (PURE) — grip strength & mortality · PubMed 25982160
2. Tang H, Inoki K, Brooks SV et al. 2019 (Aging Cell) — mTORC1 chronically hyperactive in aged mouse + human muscle; TSC1-KO model: oxidative damage,… · PubMed 30924297
3. Castets P, Rüegg MA et al. 2013 (Cell Metab) — TSC1-deficient mice: sustained mTORC1 → Ulk1 inhibition → autophagy block (overrides FoxO3) →… · PubMed 23602450
4. FMF — Rhonda Patrick + Stuart Phillips: protein + muscle
5. Peterson MD, Rhea MR, Sen A, Gordon PM. 2011 (Med Sci Sports Exerc) — Meta-analysis of 49 studies (n=1,328; adults ≥50); pooled LBM gain from RT =… · PubMed 20543750
6. Liu CJ, Latham NK. 2009 (Cochrane Database Syst Rev) — Progressive resistance training in older adults; 121 RCTs, ~6,700 participants; SMD 0.84 for… · PubMed 19588334
7. Watson et al. 2018 J Bone Miner Res — LIFTMOR trial: HiRIT in postmenopausal women with osteopenia/osteoporosis; lumbar spine BMD ↑ ~4% · PubMed 28975661
8. Morton et al. 2018, BJSM — protein + RT meta (1.6 g/kg) · PubMed 28698222
9. Desai et al. 2025, Nutrients 17(6):1081 — creatine washout LBM RCT · PubMed 40292479
10. Kreider et al. 2017 — ISSN creatine position stand · PubMed 28615996
11. Chilibeck et al. 2017 — creatine+RT lean mass meta (older) · PubMed 29138605
12. Smith GI, Julliand S, Reeds DN, Sinacore DR, Klein S, Mittendorfer B (AJCN 2015; n=44; ages 60–85; Washington U) — ~3.36g/day EPA+DHA × 6 months;… · PubMed 25994567
13. Alkhedhairi SAA, Gray SR (corresponding; Glasgow; Clin. Nutr. 2022; n=102 adults >65; NCT04048096) — krill oil 4g/day × 6 months; significantly ↑… · PubMed 35504165
14. McGlory C, Gorissen SHM et al. (FASEB Journal 2019; n=20 young women; McMaster/Phillips lab) — 5g/day fish oil × 4-wk pre-load; 2-wk… · PubMed 30629458
15. GLP-1 body composition — ~40% lean-mass loss (STEP/SURMOUNT DXA) · PubMed 39996356
16. Lincoff et al. 2023 (SELECT), NEJM — semaglutide & CV events · PubMed 37952131
17. Yang C et al. 2026 (JISSN) — NMN in BFR exercise (n=11 untrained men, crossover); anti-inflammatory effect confirmed but ALSO abolishes normal… · PubMed 41705654
18. Huberman — Gabrielle Lyon: muscle-centric medicine + longevity
19. Von Ruff LZ, Pahor M et al. 2025 (GeroScience) — n=10 men, age 72 ± 4.9y, 12-week supervised RT, vastus lateralis RNA-seq; SASP mRNAs (IL6, CXCL8,… · PubMed 40011348
20. Systematic review — BMC Geriatrics 2026; 3 RCTs, n=1,447, age 66–79y; (a) none of the RCTs measured p16 or p21 — canonical markers entirely absent… · PubMed 41652340
21. Petrocelli JJ et al. 2023 (Aging Cell) — RCT (metformin vs placebo); n=20, age ≥60y; 5-day bed rest + 7-day re-ambulation; p21, p53, SA-β-gal, p16… · PubMed 37486024